Mass spectrometry for the study of autism and neurodevelopmental disorders

Advances in Experimental Medicine and Biology

Volumn 806, Issue , 2014, Pages 525-544

  Wetie, Arm G Ngounou ^a   Dekroon, Robert M ^b   Mocanu, Mihaela ^b   Ryan, Jeanne P ^c   Darie, Costel C ^a   Woods, Alisa G ^a,c  

^a CLARKSON UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A4; APOLIPOPROTEIN B100;

ARTICLE; AUTISM; DISEASE ASSOCIATION; FRAGILE X SYNDROME; HUMAN; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEOMICS; SMITH LEMLI OPITZ SYNDROME; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; ANIMAL; METABOLISM; METHODOLOGY; REVIEW;

ANIMALS; AUTISTIC DISORDER; FRAGILE X SYNDROME; HUMANS; MASS SPECTROMETRY; PROTEOMICS; SMITH-LEMLI-OPITZ SYNDROME;

EID: 84907424668     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-06068-2_26     Document Type: Article

References (126)

1. Wormwood K, Sokolowska I, Ryan JP, Russell S, Darie CC, Woods AG (2013) The potential for proteomics in understanding neurodevelopmental disorders. J Proteom Bioinform S5
2. Junaid MA, Pullarkat RK (2001) Proteomic approach for the elucidation of biological defects in autism. J Autism Dev Disord 31:557-560
3. Anderson L, Seilhamer J (1997) A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18:533-537
4. Darie C (2013) Post-translational modification (PTM) proteomics: challenges and perspectives. Mod Chem Appl 1:e114
5. Darie CC, Shetty V, Spellman DS, Zhang G, Xu C, Cardasis HL, Blais S, Fenyo D, Neubert TA (2008) Blue native PAGE and mass spectrometry analysis of the ephrin stimulationdependent protein-protein interactions in NG108-EphB2 cells. Springer, Düsseldorf, Germany
6. Darie CC, Deinhardt K, Zhang G, Cardasis HS, Chao MV, Neubert TA (2011) Identifying transient protein-protein interactions in EphB2 signaling by blue native PAGE and mass spectrometry. Proteomics 11:4514-4528
7. Ngounou Wetie AG, Sokolowska I, Woods AG, Darie CC (2013) Identification of posttranslational modifications by mass spectrometry. Aust J Chem 66:734-748
8. Ngounou Wetie AG, Sokolowska I, Woods AG, Roy U, Deinhardt K, Darie CC (2014) Protein-protein interactions: switch from classical methods to proteomics and bioinformaticsbased approaches. Cell Mol Life Sci 71:205-228
9. Ngounou Wetie AG, Sokolowska I, Woods AG, Roy U, Loo JA, Darie CC (2012) Investigation of stable and transient protein-protein interactions: past, present, and future. Proteomics 13:538-557
10. Ngounou Wetie AG, Sokolowska I, Woods AG, Wormwood KL, Dao S, Patel S, Clarkson BD, Darie CC (2013) Automated mass spectrometry-based functional assay for the routine analysis of the secretome. J Lab Autom 18:19-29
11. Sokolowska I, Dorobantu C, Woods AG, Macovei A, Branza-Nichita N, Darie CC (2012) Proteomic analysis of plasma membranes isolated from undifferentiated and differentiated HepaRG cells. Proteome Sci 10:47
12. Sokolowska I, Gawinowicz MA, Ngounou Wetie AG, Darie CC (2012) Disulfide proteomics for identification of extracellular or secreted proteins. Electrophoresis 33:2527-2536
13. Sokolowska I, Ngounou Wetie AG, Roy U, Woods AG, Darie CC (2013) Mass spectrometry investigation of glycosylation on the NXS/T sites in recombinant glycoproteins. Biochim Biophys Acta 1834:1474-1483
14. Sokolowska I, Ngounou Wetie AG, Woods AG, Darie CC (2012) Automatic determination of disulfide bridges in proteins. J Lab Autom 17:408-416
15. Sokolowska I, Ngounou Wetie AG, Wormwood K, Michel TM, Thome J, Darie CC, Woods AG (2013) The potential of biomarkers in psychiatry: focus on proteomics. J Neural Transm 1-10
16. Woods AG, Sokolowska I, Darie CC (2012) Identification of consistent alkylation of cysteineless peptides in a proteomics experiment. Biochem Biophys Res Commun 419:305-308
17. Woods AG, Sokolowska I, Yakubu R, Butkiewicz M, LaFleur M, Talbot C, Darie CC (2011) Blue native page and mass spectrometry as an approach for the investigation of stable and transient protein-protein interactions. In: Andreescu S, Hepel M (eds) Oxidative stress: diagnostics, prevention, and therapy. American Chemical Society, Washington, DC
18. Darie C (2013) Mass spectrometry and proteomics: principle, workflow, challenges and perspectives. Mod Chem Appl 1:e105
19. Darie CC, Litscher ES, Wassarman PM (2008) Structure, processing, and polymerization of rainbow trout egg vitelline envelope proteins. Springer, Düsseldorf, Germany
20. Darie CC (2013) Mass spectrometry and its application in life sciences. Aust J Chem 66:1-2
21. Ngounou Wetie AG, Sokolowska I, Wormwood K, Michel TM, Thome J, Darie CC, Woods AG (2013) Mass spectrometry for the detection of potential psychiatric biomarkers. J Mol Psychiatry 1:8
22. Sokolowska I, Ngounou Wetie AG, Woods AG, Darie CC (2013) Applications of mass spectrometry in proteomics. Aust J Chem 66:721-733
23. Woods AG, Sokolowska I, Taurines R, Gerlach M, Dudley E, Thome J, Darie CC (2012) Potential biomarkers in psychiatry: focus on the cholesterol system. J Cell Mol Med 16:1184-1195
24. Woods AG, Ngounou Wetie AG, Sokolowska I, Russell S, Ryan JP, Michel TM, Thome J, Darie CC (2013) Mass spectrometry as a tool for studying autism spectrum disorder. J Mol Psychiatry 1:6
25. Thomas RH, Foley KA, Mepham JR, Tichenoff LJ, Possmayer F, MacFabe DF (2010) Altered brain phospholipid and acylcarnitine profiles in propionic acid infused rodents: further development of a potential model of autism spectrum disorders. J Neurochem 113:515-529
26. Klemmer P, Meredith RM, Holmgren CD, Klychnikov OI, Stahl-Zeng J, Loos M, van der Schors RC, Wortel J, de Wit H, Spijker S, Rotaru DC, Mansvelder HD, Smit AB, Li KW (2011) Proteomics, ultrastructure, and physiology of hippocampal synapses in a fragile X syndrome mouse model reveal presynaptic phenotype. J Biol Chem 286:25495-25504
27. Lista S, Faltraco F, Prvulovic D, Hampel H (2013) Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog Neurobiol 101-102:1-17
28. Shi T, Su D, Liu T, Tang K, Camp DG II, Qian WJ, Smith RD (2012) Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics. Proteomics 12:1074-1092
29. Stalmach A, Albalat A, Mullen W, Mischak H (2013) Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications. Electrophoresis 34:1452-1464
30. Amado FM, Ferreira RP, Vitorino R (2013) One decade of salivary proteomics: current approaches and outstanding challenges. Clin Biochem 46:506-517
31. Righetti PG, Boschetti E, Candiano G (2012) Mark Twain: how to fathom the depth of your pet proteome. J Proteome 75:4783-4791
32. Hu S, Li Y, Wang J, Xie Y, Tjon K, Wolinsky L, Loo RR, Loo JA, Wong DT (2006) Human saliva proteome and transcriptome. J Dent Res 85:1129-1133
33. APA (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Arlington, VA
34. Woods AG, Mahdavi E, Ryan JP (2013) Treating clients with Asperger's syndrome and autism. Child Adolesc Psychiatry Ment Health 7:32
35. APA (2000) Diagnostic and statistical manual of mental disorders (4th text revision). American Psychiatric Association, Arlington, VA
36. Autism and Developmental Disabilities Monitoring Network Surveillance Year Principal Investigators, Centers for Disease Control, and Prevention (2012) Prevalence of autism spectrum disorders-Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 61:1-19
37. Blumberg SJ, Bramlett MD, Kogan MD, Schieve LA, Jones JR, Lu MC (2013) Changes in prevalence of parent-reported autism spectrum disorder in school-aged U.S. children: 2007 to 2011-2012. National Health Statistics reports; no 65. (Department of Health and Human Services). Centers for Disease Control and Prevention, National Center for Health Statistics, Hyattsville, MD
38. Zhu L, Wang X, Li XL, Towers A, Cao X, Wang P, Bowman R, Yang H, Goldstein J, Li YJ, Jiang YH (2014) Epigenetic dysregulation of SHANK3 in brain tissues from individuals with autism spectrum disorders. Hum Mol Genet 23:1563-1578
39. Volk HE, Kerin T, Lurmann F, Hertz-Picciotto I, McConnell R, Campbell DB (2013) Autism spectrum disorder: interaction of air pollution with the MET receptor tyrosine kinase gene. Epidemiology 25:44-47
40. State MW, Levitt P (2011) The conundrums of understanding genetic risks for autism spectrum disorders. Nat Neurosci 14:1499-1506
41. Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter M (1995) Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 25:63-77
42. Le Couteur A, Bailey A, Goode S, Pickles A, Robertson S, Gottesman I, Rutter M (1996) A broader phenotype of autism: the clinical spectrum in twins. J Child Psychol Psychiatry 37:785-801
43. Betancur C (2011) Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res 1380:42-77
44. Nickl-Jockschat T, Michel TM (2011) Genetic and brain structure anomalies in autism spectrum disorders. Towards an understanding of the aetiopathogenesis? Nervenarzt 82:618-627
45. Neale BM, Kou Y, Liu L, Ma'ayan A, Samocha KE, Sabo A, Lin CF, Stevens C, Wang LS, Makarov V, Polak P, Yoon S, Maguire J, Crawford EL, Campbell NG, Geller ET, Valladares O, Schafer C, Liu H, Zhao T, Cai G, Lihm J, Dannenfelser R, Jabado O, Peralta Z, Nagaswamy U, Muzny D, Reid JG, Newsham I, Wu Y, Lewis L, Han Y, Voight BF, Lim E, Rossin E, Kirby A, Flannick J, Fromer M, Shakir K, Fennell T, Garimella K, Banks E, Poplin R, Gabriel S, DePristo M, Wimbish JR, Boone BE, Levy SE, Betancur C, Sunyaev S, Boerwinkle E, Buxbaum JD, Cook EH Jr, Devlin B, Gibbs RA, Roeder K, Schellenberg GD, Sutcliffe JS, Daly MJ (2012) Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 485:242-245
46. Leblond CS, Heinrich J, Delorme R, Proepper C, Betancur C, Huguet G, Konyukh M, Chaste P, Ey E, Rastam M, Anckarsater H, Nygren G, Gillberg IC, Melke J, Toro R, Regnault B, Fauchereau F, Mercati O, Lemiere N, Skuse D, Poot M, Holt R, Monaco AP, Jarvela I, Kantojarvi K, Vanhala R, Curran S, Collier DA, Bolton P, Chiocchetti A, Klauck SM, Poustka F, Freitag CM, Waltes R, Kopp M, Duketis E, Bacchelli E, Minopoli F, Ruta L, Battaglia A, Mazzone L, Maestrini E, Sequeira AF, Oliveira B, Vicente A, Oliveira G, Pinto D, Scherer SW, Zelenika D, Delepine M, Lathrop M, Bonneau D, Guinchat V, Devillard F, Assouline B, Mouren MC, Leboyer M, Gillberg C, Boeckers TM, Bourgeron T (2012) Genetic and func- tional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genet 8:e1002521
47. Eapen V, Crncec R, Walter A (2013) Exploring links between genotypes, phenotypes, and clinical predictors of response to early intensive behavioral intervention in autism spectrum disorder. Front Hum Neurosci 7:567
48. Lanz TA, Guilmette E, Gosink MM, Fischer JE, Fitzgerald LW, Stephenson DT, Pletcher MT (2013) Transcriptomic analysis of genetically defined autism candidate genes reveals common mechanisms of action. Mol Autism 4:45
49. Gurrieri F (2012) Working up autism: the practical role of medical genetics. Am J Med Genet C Semin Med Genet 160C:104-110
50. Lee TL, Raygada MJ, Rennert OM (2012) Integrative gene network analysis provides novel regulatory relationships, genetic contributions and susceptible targets in autism spectrum disorders. Gene 496:88-96
51. Carter MT, Scherer SW (2013) Autism spectrum disorder in the genetics clinic: a review. Clin Genet 83:399-407
52. Nickl-Jockschat T, Michel TM (2011) The role of neurotrophic factors in autism. Mol Psychiatry 16:478-490
53. Theoharides TC, Kempuraj D, Redwood L (2009) Autism: an emerging 'neuroimmune disorder' in search of therapy. Expert Opin Pharmacother 10:2127-2143
54. Veenstra-VanderWeele J, Blakely RD (2012) Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments. Neuropsychopharmacology 37:196-212
55. Lord C, Risi S, Lambrecht L, Cook EH, Leventhal BL, DiLavore PC, Pickles A, Rutter M (2000) The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 30:205-223
56. Lord C, Risi S, DiLavore PS, Shulman C, Thurm A, Pickles A (2006) Autism from 2 to 9 years of age. Arch Gen Psychiatry 63:694-701
57. Dereu M, Roeyers H, Raymaekers R, Meirsschaut M, Warreyn P (2012) How useful are screening instruments for toddlers to predict outcome at age 4? General development, language skills, and symptom severity in children with a false positive screen for autism spectrum disorder. Eur Child Adolesc Psychiatry 21:541-551
58. Lam KS, Aman MG, Arnold LE (2006) Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 27:254-289
59. Cass H, Gringras P, March J, McKendrick I, O'Hare AE, Owen L, Pollin C (2008) Absence of urinary opioid peptides in children with autism. Arch Dis Child 93:745-750
60. Hunter LC, O'Hare A, Herron WJ, Fisher LA, Jones GE (2003) Opioid peptides and dipeptidyl peptidase in autism. Dev Med Child Neurol 45:121-128
61. Dettmer K, Hanna D, Whetstone P, Hansen R, Hammock BD (2007) Autism and urinary exogenous neuropeptides: development of an on-line SPE-HPLC-tandem mass spectrometry method to test the opioid excess theory. Anal Bioanal Chem 388:1643-1651
62. Albizzati A, More L, Di Candia D, Saccani M, Lenti C (2012) Normal concentrations of heavy metals in autistic spectrum disorders. Minerva Pediatr 64:27-31
63. Owens SE, Summar ML, Ryckman KK, Haines JL, Reiss S, Summar SR, Aschner M (2011) Lack of association between autism and four heavy metal regulatory genes. Neurotoxicology 32:769-775
64. Montaser A, McLean JA, Liu H, Mermet J-M (1998) An introduction to ICP spectrometries for elemental analysis. In: Montaser A (ed) Plasma mass spectrometry. Wiley, Hoboken, NJ
65. Soden SE, Lowry JA, Garrison CB, Wasserman GS (2007) 24-hour provoked urine excretion test for heavy metals in children with autism and typically developing controls, a pilot study. Clin Toxicol 45:476-481
66. Kern JK, Grannemann BD, Trivedi MH, Adams JB (2007) Sulfhydryl-reactive metals in autism. J Toxic Environ Health A 70:715-721
67. Hertz-Picciotto I, Croen LA, Hansen R, Jones CR, van de Water J, Pessah IN (2006) The CHARGE study: an epidemiologic investigation of genetic and environmental factors contributing to autism. Environ Health Perspect 114:1119-1125
68. Hertz-Picciotto I, Green PG, Delwiche L, Hansen R, Walker C, Pessah IN (2010) Blood mercury concentrations in CHARGE Study children with and without autism. Environ Health Perspect 118:161-166
69. Hertz-Picciotto I, Bergman A, Fangstrom B, Rose M, Krakowiak P, Pessah I, Hansen R, Bennett DH (2011) Polybrominated diphenyl ethers in relation to autism and developmental delay: a case-control study. Environ Heal 10:1
70. Russo AJ, Devito R (2011) Analysis of copper and zinc plasma concentration and the efficacy of zinc therapy in individuals with Asperger's syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS) and autism. Biomark Insights 6:127-133
71. Taurines R, Dudley E, Conner AC, Grassl J, Jans T, Guderian F, Mehler-Wex C, Warnke A, Gerlach M, Thome J (2010) Serum protein profiling and proteomics in autistic spectrum disorder using magnetic bead-assisted mass spectrometry. Eur Arch Psychiatry Clin Neurosci 260:249-255
72. Taurines R, Dudley E, Grassl J, Warnke A, Gerlach M, Coogan AN, Thome J (2011) Proteomic research in psychiatry. J Psychopharmacol 25:151-196
73. Corbett BA, Kantor AB, Schulman H, Walker WL, Lit L, Ashwood P, Rocke DM, Sharp FR (2007) A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins. Mol Psychiatry 12:292-306
74. Momeni N, Brudin L, Behnia F, Nordstrom B, Yosefi -Oudarji A, Sivberg B, Joghataei MT, Persson BL (2012) High complement factor I activity in the plasma of children with autism spectrum disorders. Autism Res Treat 2012:868576
75. Momeni N, Bergquist J, Brudin L, Behnia F, Sivberg B, Joghataei MT, Persson BL (2012) A novel blood-based biomarker for detection of autism spectrum disorders. Transl Psychiatry 2:e91
76. Unlu M, Morgan ME, Minden JS (1997) Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18:2071-2077
77. Lilley KS, Razzaq A, Dupree P (2002) Two-dimensional gel electrophoresis: recent advances in sample preparation, detection and quantitation. Curr Opin Chem Biol 6:46-50
78. Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J, Pognan F, Hawkins E, Currie I, Davison M (2001) Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 1:377-396
79. DeKroon RM, Osorio C, Robinette JB, Mocanu M, Winnik WM, Alzate O (2011) Simultaneous detection of changes in protein expression and oxidative modification as a function of age and APOE genotype. J Proteome Res 10:1632-1644
80. DeKroon RM, Robinette JB, Osorio C, Jeong JS, Hamlett E, Mocanu M, Alzate O (2012) Analysis of protein posttranslational modifications using DIGE-based proteomics. Methods Mol Biol 854:129-143
81. Londono C, DeKroon RM, Mocanu M, Booe J, Winnik WM, Swank A, Osorio C, Hamlett ED, Alzate O (2012) Proteomic analysis of mice expressing human ApoE demonstrates no differences in global protein solubility between APOE 3 and APOE 4 young mice. Electrophoresis 33:3745-3755
82. Petrareanu C, Macovei A, Sokolowska I, Woods AG, Lazar C, Radu GL, Darie CC, Branza- Nichita N (2013) Comparative proteomics reveals novel components at the plasma membrane of differentiated HepaRG cells and different distribution in hepatocyte-and biliary-like cells. PLoS One 8:e71859
83. Roy U, Sokolowska I, Woods AG, Darie CC (2012) Structural investigation of tumor differentiation factor. Biotechnol Appl Biochem 59:445-450
84. Winnik WM, Dekroon RM, Jeong JS, Mocanu M, Robinette JB, Osorio C, Dicheva NN, Hamlett E, Alzate O (2012) Analysis of proteins using DIGE and MALDI mass spectrometry. Methods Mol Biol 854:47-66
85. Emanuele E, Colombo R, Martinelli V, Brondino N, Marini M, Boso M, Barale F, Politi P (2010) Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia. Neuro Endocrinol Lett 31:117-121
86. Kałuzna-Czaplinska J, Michalska M, Rynkowski J (2010) Determination of tryptophan in urine of autistic and healthy children by gas chromatography/mass spectrometry. Med Sci Monit 16:CR488-CR492
87. Pedersen OS, Liu Y, Reichelt KL (1999) Serotonin uptake stimulating peptide found in plasma of normal individuals and in some autistic urines. J Pept Res 53:641-646
88. Sokolowska I, Woods AG, Wagner J, Dorler J, Wormwood K, Thome J, Darie CC (2011) Mass spectrometry for proteomics-based investigation of oxidative stress and heat shock proteins. In: Andreescu S, Hepel M (eds) Oxidative stress: diagnostics, prevention, and therapy. American Chemical Society, Washington, DC
89. Ghanizadeh A, Akhondzadeh S, Hormozi M, Makarem A, Abotorabi-Zarchi M, Firoozabadi A (2012) Glutathione-related factors and oxidative stress in autism, a review. Curr Med Chem 19:4000-4005
90. Yao Y, Walsh WJ, McGinnis WR, Pratico D (2006) Altered vascular phenotype in autism: correlation with oxidative stress. Arch Neurol 63:1161-1164
91. Shi M, Sui YT, Peskind ER, Li G, Hwang H, Devic I, Ginghina C, Edgar JS, Pan C, Goodlett DR, Furay AR, Gonzalez-Cuyar LF, Zhang J (2011) Salivary tau species are potential biomarkers of Alzheimer's disease. J Alzheimers Dis 27:299-305
92. Castagnola M, Messana I, Inzitari R, Fanali C, Cabras T, Morelli A, Pecoraro AM, Neri G, Torrioli MG, Gurrieri F (2008) Hypo-phosphorylation of salivary peptidome as a clue to the molecular pathogenesis of autism spectrum disorders. J Proteome Res 7:5327-5332
93. Brown W (2002) The molecular biology of fragile X mutation. In: Hagerman R, Hagerman PJ (eds) Fragile X syndrome: diagnosis, treatment, and research. Johns Hopkins University Press, Baltimore, MD, pp 110-135
94. De Rubeis S, Fernandez E, Buzzi A, Di Marino D, Bagni C (2012) Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis. Adv Exp Med Biol 970:517-551
95. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, Kronk R, Delahunty C, Hessl D, Visootsak J, Picker J, Gane L, Tranfaglia M (2009) Advances in the treatment of fragile X syndrome. Pediatrics 123:378-390
96. McCary LM, Roberts JE (2012) Early identification of autism in fragile X syndrome: a review. J Intellect Disabil Res 57:803-814
97. Boyle L, Kaufmann WE (2010) The behavioral phenotype of FMR1 mutations. Am J Med Genet C: Semin Med Genet 154C:469-476
98. Hagerman R, Lauterborn J, Au J, Berry-Kravis E (2012) Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ 54:297-335
99. Smith LE, Barker ET, Seltzer MM, Abbeduto L, Greenberg JS (2012) Behavioral phenotype of fragile X syndrome in adolescence and adulthood. Am J Intellect Dev Disabil 117:1-17
100. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, Carpenter RL, Bear MF, Hagerman RJ (2012) Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 4:152ra127
101. Dziembowska M, Pretto DI, Janusz A, Kaczmarek L, Leigh MJ, Gabriel N, Durbin-Johnson B, Hagerman RJ, Tassone F (2013) High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A 161A:1897-1903
102. Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, Polussa J, Doucet P, Tassone F, Rivera SM, Hessl D, Hagerman RJ (2013) A randomized double-blind, placebocontrolled trial of minocycline in children and adolescents with fragile X syndrome. J Dev Behav Pediatr 34:147-155
103. Jacquemont S, Berry-Kravis E, Hagerman R, von Raison F, Gasparini F, Apostol G, Ufer M, Des Portes V, Gomez-Mancilla B (2014) The challenges of clinical trials in fragile X syndrome. Psychopharmacology 231:1237-1250
104. Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK, Outcome Measures Working G (2013) Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr 34:508-522
105. Darie CC, Biniossek ML, Gawinowicz MA, Milgrom Y, Thumfart JO, Jovine L, Litscher ES, Wassarman PM (2005) Mass spectrometric evidence that proteolytic processing of rainbow trout egg vitelline envelope proteins takes place on the egg. J Biol Chem 280:37585-37598
106. Liao L, Park SK, Xu T, Vanderklish P, Yates JR III (2008) Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice. Proc Natl Acad Sci U S A 105:15281-15286
107. Monzo K, Dowd SR, Minden JS, Sisson JC (2010) Proteomic analysis reveals CCT is a target of Fragile X mental retardation protein regulation in Drosophila. Dev Biol 340: 408-418
108. Zhang YQ, Friedman DB, Wang Z, Woodruff E III, Pan L, O'Donnell J, Broadie K (2005) Protein expression profiling of the drosophila fragile X mutant brain reveals up-regulation of monoamine synthesis. Mol Cell Proteomics 4:278-290
109. Zhang YQ, Matthies HJ, Mancuso J, Andrews HK, Woodruff E III, Friedman D, Broadie K (2004) The Drosophila fragile X-related gene regulates axoneme differentiation during spermatogenesis. Dev Biol 270:290-307
110. Xu P, Tan H, Duong DM, Yang Y, Kupsco J, Moberg KH, Li H, Jin P, Peng J (2012) Stable isotope labeling with amino acids in Drosophila for quantifying proteins and modifications. J Proteome Res 11:4403-4412
111. Kaufmann WE, Cohen S, Sun HT, Ho G (2002) Molecular phenotype of Fragile X syndrome: FMRP, FXRPs, and protein targets. Microsc Res Tech 57:135-144
112. Godler DE, Slater HR, Bui QM, Ono M, Gehling F, Francis D, Amor DJ, Hopper JL, Hagerman R, Loesch DZ (2011) FMR1 intron 1 methylation predicts FMRP expression in blood of female carriers of expanded FMR1 alleles. J Mol Diagn 13:528-536
113. Godler DE, Slater HR, Bui QM, Storey E, Ono MY, Gehling F, Inaba Y, Francis D, Hopper JL, Kinsella G, Amor DJ, Hagerman RJ, Loesch DZ (2012) Fragile X mental retardation 1 (FMR1) intron 1 methylation in blood predicts verbal cognitive impairment in female carriers of expanded FMR1 alleles: evidence from a pilot study. Clin Chem 58:590-598
114. Aneja A, Tierney E (2008) Autism: the role of cholesterol in treatment. Int Rev Psychiatry 20:165-170
115. Bukelis I, Porter FD, Zimmerman AW, Tierney E (2007) Smith-Lemli-Opitz syndrome and autism spectrum disorder. Am J Psychiatry 164:1655-1661
116. Diaz-Stransky A, Tierney E (2012) Cognitive and behavioral aspects of Smith-Lemli-Opitz syndrome. Am J Med Genet C: Semin Med Genet 160C:295-300
117. Tierney E, Bukelis I, Thompson RE, Ahmed K, Aneja A, Kratz L, Kelley RI (2006) Abnormalities of cholesterol metabolism in autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet 141B:666-668
118. DeBarber AE, Eroglu Y, Merkens LS, Pappu AS, Steiner RD (2011) Smith-Lemli-Opitz syndrome. Exp Rev Mol Med 13:e24
119. Fitzky BU, Moebius FF, Asaoka H, Waage-Baudet H, Xu L, Xu G, Maeda N, Kluckman K, Hiller S, Yu H, Batta AK, Shefer S, Chen T, Salen G, Sulik K, Simoni RD, Ness GC, Glossmann H, Patel SB, Tint GS (2001) 7-Dehydrocholesterol-dependent proteolysis of HMG-CoA reductase suppresses sterol biosynthesis in a mouse model of Smith-Lemli-Opitz/ RSH syndrome. J Clin Invest 108:905-915
120. Corso G, Gelzo M, Barone R, Clericuzio S, Pianese P, Nappi A, Dello Russo A (2011) Sterol profiles in plasma and erythrocyte membranes in patients with Smith-Lemli-Opitz syndrome: a six-year experience. Clin Chem Lab Med 49:2039-2046
121. Griffiths WJ, Wang Y, Karu K, Samuel E, McDonnell S, Hornshaw M, Shackleton C (2008) Potential of sterol analysis by liquid chromatography-tandem mass spectrometry for the prenatal diagnosis of Smith-Lemli-Opitz syndrome. Clin Chem 54:1317-1324
122. Meljon A, Watson GL, Wang Y, Shackleton CH, Griffiths WJ (2013) Analysis by liquid chromatography-mass spectrometry of sterols and oxysterols in brain of the newborn Dhcr7(Delta3-5/T93M) mouse: a model of Smith-Lemli-Opitz syndrome. Biochem Pharmacol 86:43-55
123. Paglia G, D'Apolito O, Gelzo M, Dello Russo A, Corso G (2010) Direct analysis of sterols from dried plasma/blood spots by an atmospheric pressure thermal desorption chemical ionization mass spectrometry (APTDCI-MS) method for a rapid screening of Smith-Lemli- Opitz syndrome. Analyst 135:789-796
124. Patti GJ, Shriver LP, Wassif CA, Woo HK, Uritboonthai W, Apon J, Manchester M, Porter FD, Siuzdak G (2010) Nanostructure-initiator mass spectrometry (NIMS) imaging of brain cholesterol metabolites in Smith-Lemli-Opitz syndrome. Neuroscience 170:858-864
125. Tu C, Li J, Jiang X, Sheflin LG, Pfeffer BA, Behringer M, Fliesler SJ, Qu J (2013) Ion current based proteomic profiling of the retina in a rat model of Smith-Lemli-Opitz syndrome. Mol Cell Proteomics 12:3583-3598
126. Fliesler SJ (2010) Retinal degeneration in a rat model of Smith-Lemli-Opitz Syndrome: thinking beyond cholesterol deficiency. Adv Exp Med Biol 664:481-489